These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38861400)

  • 21. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.
    van de Borne P; Peeters A; Janssens L; Leone A; Lemmens R; Verhaegen A; De Meulemeester M; Balthazar Y; Heijmans S; Calozet Y; Paquot N; Carlier S; Hemelsoet D; Bray S; Ray KK
    Acta Cardiol; 2024 Feb; 79(1):20-29. PubMed ID: 35442151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in atherosclerotic cardiovascular disease and lipid management: a population-level observational cohort study in Wales.
    Harris DE; King D; Akbari A; Gravenor M; Lawrence M; Weston C; Hopkins C; Phillips L; Halcox J
    Eur J Prev Cardiol; 2024 Nov; 31(15):1778-1789. PubMed ID: 39036983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
    Paragh G; Márk L; Zámolyi K; Pados G; Ofner P
    Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study.
    Gavina C; Seabra-Carvalho D; Aguiar C; Anastassopoulou A; Teixeira C; Ruivo JA; Almeida É; Luz-Duarte L; Corte-Real A; Canelas-Pais M; Taveira-Gomes T
    Clin Cardiol; 2024 Jan; 47(1):e24183. PubMed ID: 37933175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
    Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
    Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis.
    Pohl SB; Engelbertz C; Reinecke H; Malyar NM; Meyborg M; Brix TJ; Varghese J; Gebauer K
    Nutr Metab Cardiovasc Dis; 2024 Jul; 34(7):1670-1680. PubMed ID: 38664125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?
    Offiah G; O'Connor C; Kennedy C; Gallagher J; O'Connor P; McAdam B; Ray KK; Schoonen M; Maher V
    Ir J Med Sci; 2023 Jun; 192(3):1077-1084. PubMed ID: 35776266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.
    Barkas F; Liberopoulos EN; Kostapanos MS; Liamis G; Tziallas D; Elisaf M
    Angiology; 2015 Apr; 66(4):346-53. PubMed ID: 24830420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Low-density Lipoprotein Cholesterol Target Attainment Rates According to the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for Secondary Prevention in Patients with Acute Myocardial Infarction.
    Şimşek B; İnan D; Çınar T; Cagdas-Yumurtaş A; Ozan-Tanık V; Zeren G; İlker-Avcı İ; Yücel-Karabay C; Güngör B; Tokgozoğlu L
    Rev Invest Clin; 2021 Nov; 73(3):371-378. PubMed ID: 34098569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.
    Vrablik M; Seifert B; Parkhomenko A; Banach M; Jóźwiak JJ; Kiss RG; Gaita D; Rašlová K; Zachlederova M; Bray S; Ray KK
    Atherosclerosis; 2021 Oct; 334():66-75. PubMed ID: 34482090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
    J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
    Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
    Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe.
    Halcox JP; Tubach F; Lopez-Garcia E; De Backer G; Borghi C; Dallongeville J; Guallar E; Medina J; Perk J; Sazova O; Sweet S; Roy C; Banegas JR; Rodriguez-Artalejo F
    PLoS One; 2015; 10(2):e0115270. PubMed ID: 25692692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study.
    Ray KK; Haq I; Bilitou A; Manu MC; Burden A; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrières J; Laufs U; Mostaza JM; Nanchen D; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL;
    Lancet Reg Health Eur; 2023 Jun; 29():100624. PubMed ID: 37090089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea.
    Kim S; Han S; Rane PP; Qian Y; Zhao Z; Suh HS
    PLoS One; 2020; 15(1):e0228472. PubMed ID: 31999714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease.
    Hess CN; Cannon CP; Beckman JA; Goodney PP; Patel MR; Hiatt WR; Mues KE; Orroth KK; Shannon E; Bonaca MP
    J Am Coll Cardiol; 2021 Jun; 77(24):3016-3027. PubMed ID: 34140105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.